The Public Consultation on the draft Evidence Guidelines for listed medicines has been published. 

A consultation period of 4 weeks has been provided, closing 1 April 2022.

This technical alert provides preliminary information on the consultation for members. Please note, CMA are currently reviewing the consultation paper and intend to provide a deeper analysis on the draft guidelines in the coming days, including advice for members on how to respond to the consultation.